Biomedical Engineering Reference
In-Depth Information
50% of all human protein kinase structures solved
by SGC (in past 5 years)
Figure 4.3
Contribution of SGC to solving protein kinase structures.
4.2.2.1 IP Policy Importantly, the SGC operates in precompetitive space
and does not generate any IP; thus the consortium is committed to placing any
results promptly into the public domain and does not fi le for patent protection
on any of its research outputs [15]. It also means that the SGC seeks the same
commitment from any of its research collaborators; despite this, the policy
does appear to confer signifi cant advantages, primarily through allowing speed
of interaction with potential collaborators. It also means that the consortium
can work with multiple private partners on the same project. The SGC cur-
rently has over 250 collaborators in 19 countries, and it is easy to access the
relevant individuals through the consortium website.
4.2.2.2 Governance The SGC is run by a chief executive and oversight is
provided by a board of directors (primarily nominated by the funders) and a
scientifi c advisory board. Operations at each of the three sites are managed
by a chief scientist and these individuals along with the CEO sit on the board
of directors.
The scientifi c committee approves the list of protein targets for the SGC to
work on and also those targets which are deprioritized. Reasons for the SGC
ceasing to work on a target include the structure being solved elsewhere,
intractability of the protein to solubilization or crystallization, or realignment
of strategic focus.
In 2009, the SGC added an additional consortium project—the International
Epigenetics Chemical Probes Consortium, which aims to stimulate epigenetics
Search WWH ::




Custom Search